Published in Arch Pathol Lab Med on June 01, 1997
Role of osteopontin in tumour progression. Br J Cancer (2004) 2.65
The tumor microenvironment and metastatic disease. Clin Exp Metastasis (2008) 1.91
Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol (2000) 1.86
Identification of early molecular markers for breast cancer. Mol Cancer (2011) 1.45
Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol (2006) 1.30
Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal (2011) 1.17
Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis (2003) 1.13
Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis (2004) 1.09
Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res (2009) 1.04
Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer (2005) 1.03
Genomic alterations in sporadic synchronous primary breast cancer using array and metaphase comparative genomic hybridization. Neoplasia (2007) 1.01
Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis (2000) 0.93
Homing of cancer cells to the bone. Cancer Microenviron (2011) 0.92
Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner. PLoS One (2012) 0.88
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res (2014) 0.87
RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer. Surgery (2008) 0.87
Overexpression of osteopontin and integrin αv in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis. J Cancer Res Clin Oncol (2011) 0.86
Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines. Br J Cancer (2004) 0.85
Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. Blood (2011) 0.84
The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype. J Cancer Res Clin Oncol (2010) 0.83
Nitric oxide-dependent osteopontin expression induces metastatic behavior in HepG2 cells. Dig Dis Sci (2005) 0.82
Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal. J Neurooncol (2007) 0.79
Structure and function of the solid tumor niche. Front Biosci (Schol Ed) (2012) 0.78
Integrin β3 and CD44 levels determine the effects of the OPN-a splicing variant on lung cancer cell growth. Oncotarget (2016) 0.77
Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol (1998) 4.41
Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet (1998) 2.75
Role of osteopontin in tumour progression. Br J Cancer (2004) 2.65
Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res (2000) 2.58
Multicentre evaluation of intraoperative molecular analysis of sentinel lymph nodes in breast carcinoma. Br J Surg (2010) 2.48
Retinoic acid-induced neural differentiation of embryonal carcinoma cells. Mol Cell Biol (1983) 2.45
Interhospital differences in severity of illness. Problems for prospective payment based on diagnosis-related groups (DRGs). N Engl J Med (1985) 2.00
Randomized trial of a specialist genetic assessment service for familial breast cancer. J Natl Cancer Inst (2000) 1.92
CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res (1999) 1.82
Early interactions of cancer cells with the microvasculature in mouse liver and muscle during hematogenous metastasis: videomicroscopic analysis. Clin Exp Metastasis (1993) 1.73
Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res (1997) 1.71
Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer (1998) 1.64
Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin Exp Metastasis (1994) 1.64
Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis. J Cell Sci (1999) 1.63
Psychiatric severity of illness. A case mix study. Med Care (1989) 1.62
CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene (1998) 1.58
Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res (1995) 1.52
Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene (1999) 1.51
Osteopontin expression in lung cancer. Lung Cancer (1996) 1.51
Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene (2006) 1.47
The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med (2001) 1.45
Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis. Gut (2005) 1.44
Induced muscle differentiation in an embryonal carcinoma cell line. Mol Cell Biol (1983) 1.41
Axillary node dissection in patients with breast cancer diagnosed through the Ontario Breast Screening Program: a need for minimally invasive techniques. Can J Surg (1997) 1.39
Granular cell tumour of the breast: MRI findings and review of the literature. Br J Radiol (2007) 1.37
The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol (2002) 1.35
Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. Hum Pathol (1997) 1.33
Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia (2007) 1.33
Severity of illness within DRGs. Homogeneity study. Med Care (1986) 1.30
Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol (2001) 1.30
Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer (1996) 1.30
Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res (1994) 1.30
Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Clin Exp Metastasis (1993) 1.27
Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol (2001) 1.27
Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well. Proc Natl Acad Sci U S A (1996) 1.25
The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia (2001) 1.24
Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem (2000) 1.24
Osteopontin and its receptor alphavbeta(3) integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differentially. J Clin Endocrinol Metab (2001) 1.23
Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res (1994) 1.23
Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun (1988) 1.22
Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Lett (1997) 1.21
The analysis of spiral growth in phycomyces using a novel optical method. Plant Physiol (1974) 1.20
Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer (1990) 1.18
Prognostic value of motor evoked potential obtained by transcranial magnetic brain stimulation in motor function recovery in patients with acute ischemic stroke. Stroke (1998) 1.17
Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids (1995) 1.16
p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst (1994) 1.13
Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem (2000) 1.12
Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res (1995) 1.08
Evaluation of general practitioner referrals to a specialist breast clinic according to the UK national guidelines. Eur J Surg Oncol (1997) 1.08
Highly sensitive nonradioactive single-strand conformational polymorphism. Detection of Ki-ras mutations. Diagn Mol Pathol (1996) 1.07
Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Proc Natl Acad Sci U S A (1997) 1.05
A model system for studying metastasis using the embryonic chick. Cancer Res (1982) 1.04
Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat (2001) 1.04
Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem (1996) 1.04
Compositional changes in developing rape seed (Brassica napus L.). Planta (1975) 1.02
Human isopentenyl diphosphate: dimethylallyl diphosphate isomerase: overproduction, purification, and characterization. Arch Biochem Biophys (1996) 1.02
Experimental metastatic ability of H-ras-transformed NIH3T3 cells. Cancer Res (1985) 1.02
Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. Science (1984) 1.01
Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. Proc Natl Acad Sci U S A (1982) 0.99
Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem (1994) 0.99
Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem (1995) 0.97
Clonal heterogeneity, experimental metastatic ability, and p21 expression in H-ras-transformed NIH 3T3 cells. J Natl Cancer Inst (1988) 0.97
Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am J Physiol (1998) 0.97
Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer (2012) 0.96
Overcoming obstacles to metastasis--defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem (1994) 0.96
Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Genet (1985) 0.95
Intravital videomicroscopy of the chorioallantoic microcirculation: a model system for studying metastasis. Microvasc Res (1992) 0.95
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet (2010) 0.94
Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol (1995) 0.94
Quantitative genetic analysis of tumor progression. Cancer Metastasis Rev (1985) 0.93
Dynamic heterogeneity and metastasis. J Cell Physiol Suppl (1984) 0.93
Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem (1994) 0.93
p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: a prospective study. Cancer Detect Prev (1994) 0.93
Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. Cancer Res (2000) 0.93
Sudden infant death syndrome in infants of substance-abusing mothers. J Pediatr (1990) 0.92
ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer (1997) 0.92